Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Summary

The purpose of this research study is to look at participants with solid tumor malignancies and specific mutations respond to treatment with everolimus.

Timeline

Start

2015-10-07

Primary completion

2017-08-15

Completion

2017-08-15

Drugs

Indications